MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces the
following changes to its Board and Executive team, effective
immediately. Scott Spearn, who joined the Company as President in April
2018 is taking on the additional role of Chief Executive Officer and is
joining the Board of Directors. Rob von der Porten, previously the CEO,
has been appointed as Chairman of the Board in place of Gary Van Nest
who has retired from that position and remains as a director.
“With the recent launch of our DermSecure™ telemedicine platform and
anticipating a global roll-out of this leading product, the transition
of Scott’s role to CEO represents a natural evolution at MedX,” noted
Rob von der Porten, MedX’s new Chairman. “Scott’s experience in building
sales organizations and developing international markets in the medical
device field will help accelerate our growth from our SIAscopy
technology and our Therapeutic and Dental Laser products.”
Gary Van Nest noted, “On behalf of the Board, we want to thank Rob von
der Porten for his leadership during challenging times over the past few
years and developing with the MedX team solid product roadmaps such as
the delivery of DermSecure™.
“I am excited to be taking on the CEO role, leading a dedicated team of
hard-working people. MedX is a great Canadian company with innovative
products and robust technology that is making a big difference in the
health of people’s lives around the world,” said Mr. Spearn.
Mr. Spearn is a seasoned medical device executive with nearly 30 years
of developing sustainable, trusted relationships with key opinion
leaders, strategic partners and industry influencers. Before joining
MedX, Mr. Spearn held a number of senior executive roles at a
multi-national medical device company where he substantially grew
revenues across several business divisions.
The Company has granted 1,000,000 share options to the incoming CEO, the
options having an exercise price of $0.16, exercisable for a period of
five years, and vesting over a one-year period.
MedX, headquartered in Mississauga, Ontario, is a leading medical device
and software company focused on skin cancer with its DermSecure™
telemedicine platform, utilizing its SIAscopy technology. SIAscopy is
also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™,
SIMSYS™, and MoleMate™ include hand-held devices that use patented
technology utilizing light and its remittance to view up to 2 mm beneath
suspicious moles and lesions in a pain free, non-invasive manner, with
its software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within seconds.
These products are Health Canada, FDA (US), ARTG and CE cleared for use
in Canada, the US, Australia, New Zealand, the European Union and
Turkey. MedX also designs, manufactures and distributes quality
photobiomodulation therapeutic and dental lasers to provide drug-free
and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events. The
forward-looking statements involve risks and uncertainties.
MedX Health Corp
Scott Spearn, 905-670-4428 ext 226